英格兰北部的红白血病：一项基于人群的研究。
Erythroleukaemia in the north of England: a population based study.
作者信息
Wells A W, Bown N, Reid M M, Hamilton P J, Jackson G H, Taylor P R
机构信息
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
出版信息
J Clin Pathol. 2001 Aug;54(8):608-12. doi: 10.1136/jcp.54.8.608.
Abstract
AIMS
To evaluate the incidence and outcome of acute myeloid leukaemia (AML), FAB M6 (erythroleukaemia).
METHODS
A demographic study in the Northern Health Region of England between 1983 and 1999.
RESULTS
Thirty three cases were diagnosed and registered prospectively. The overall incidence was 0.077 cases/100,000/year. There was a pronounced rise in incidence in patients aged 56 years or more: 6.6 times higher than that in younger patients. Overall survival was poor; median survival was 11 months for those aged less than 56 years, and three months for patients aged 56 years and above (p = 0.045). Acquired karyotypic abnormalities were found in 17 of 27 patients where analysis was attempted. When classified according to the criteria of the Medical Research Council AML trials, karyotype predicted survival, with a median overall survival of 14 months for those with "standard risk" cytogenetic results and two months for "poor risk" results (p = 0.005).
CONCLUSION
This study demonstrates a worse survival for patients with erythroleukaemia than that reported in some published trials of selected patients.
摘要
目的
评估急性髓系白血病（AML）FAB M6型（红白血病）的发病率及预后。
方法
对1983年至1999年间英格兰北部健康区域进行一项人口统计学研究。
结果
前瞻性诊断并登记了33例病例。总体发病率为0.077例/10万/年。56岁及以上患者的发病率显著上升：比年轻患者高6.6倍。总体生存率较差；年龄小于56岁者的中位生存期为11个月，56岁及以上患者为3个月（p = 0.045）。在27例尝试进行分析的患者中，17例发现了获得性核型异常。根据医学研究委员会AML试验的标准进行分类时，核型可预测生存情况，“标准风险”细胞遗传学结果者的中位总生存期为14个月，“高风险”结果者为2个月（p = 0.005）。
结论
本研究表明，红白血病患者的生存情况比一些已发表的特定患者试验报告的情况更差。
相似文献
1
Erythroleukaemia in the north of England: a population based study.英格兰北部的红白血病：一项基于人群的研究。
J Clin Pathol. 2001 Aug;54(8):608-12. doi: 10.1136/jcp.54.8.608.
2
Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation.13号染色体四体作为急性髓系白血病M1型（无成熟型）的唯一细胞遗传学异常。
Cancer Genet Cytogenet. 2002 Jun;135(2):192-5. doi: 10.1016/s0165-4608(01)00651-3.
3
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.优化年轻急性髓细胞白血病患者的化疗：英国医学研究理事会 AML15 试验的结果。
J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.
4
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.儿童复发性急性髓系白血病的改善结局：国际 BFM 研究组进行的脂质体柔红霉素随机试验的结果。
J Clin Oncol. 2013 Feb 10;31(5):599-607. doi: 10.1200/JCO.2012.43.7384. Epub 2013 Jan 14.
5
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.采用伊达比星、阿糖胞苷、依托泊苷及粒细胞集落刺激因子预激进行强化化疗治疗晚期骨髓增生异常综合征和高危急性髓系白血病患者。
Ann Hematol. 2004 Aug;83(8):498-503. doi: 10.1007/s00277-004-0889-0. Epub 2004 May 20.
6
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].[急性髓系白血病的治疗——单中心经验（2007 - 2013年）]
Orv Hetil. 2014 Apr 27;155(17):653-8. doi: 10.1556/OH.2014.29884.
7
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.脂质体柔红霉素、氟达拉滨和阿糖胞苷（FLAD）作为桥接治疗在复发和难治性急性白血病中进行干细胞移植。
Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.
8
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.6-硫鸟嘌呤、阿糖胞苷和柔红霉素（TAD）以及高剂量阿糖胞苷和米托蒽醌（HAM）用于诱导治疗，TAD用于巩固治疗，对于各年龄段初发急性髓系白血病（AML）的成年患者，采用每月减量的TAD进行长期维持治疗或TAD-HAM-TAD方案，以及通过序贯HAM进行一个疗程的强化巩固治疗：德国AML协作组的一项随机试验
J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133.
9
10
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.高剂量阿糖胞苷诱导治疗可改善年龄<46 岁成人急性髓系白血病患者的预后：EORTC-GIMEMA AML-12 试验结果。
J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.
引用本文的文献
1
MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.微小RNA与JAK/STAT3信号传导：血液系统恶性肿瘤中一个新的有前景的治疗靶点
Genes Dis. 2021 Dec 3;9(4):849-867. doi: 10.1016/j.gendis.2021.10.009. eCollection 2022 Jul.
2
Alpha-Synuclein Expression in Acute Erythroleukaemia, Acute Megakaryoblastic Leukemia, and Normal Counterparts in Bone Marrow.α-突触核蛋白在急性红白血病、急性巨核细胞白血病及骨髓正常对照中的表达
Iran J Pathol. 2017 Winter;12(1):74-78. Epub 2016 Aug 30.
3
An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification.对97例先前诊断的初发成年急性红系白血病患者按照2016年世界卫生组织分类修订版进行的分析。
BMC Cancer. 2017 Aug 9;17(1):534. doi: 10.1186/s12885-017-3528-6.
4
Clinical Characteristics and Prognosis of 167 Cases of Acute Erythroleukemia.167例急性红白血病的临床特征与预后
Indian J Hematol Blood Transfus. 2017 Mar;33(1):56-60. doi: 10.1007/s12288-016-0671-1. Epub 2016 Apr 8.
5
Study of clinical, haematological and cytogenetic profile of patients with acute erythroid leukaemia.急性红系白血病患者的临床、血液学及细胞遗传学特征研究
Ecancermedicalscience. 2017 Jan 10;11:712. doi: 10.3332/ecancer.2017.712. eCollection 2017.
6
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.伴有<20%骨髓原始细胞的急性红细胞白血病在临床上和生物学上与伴有过多原始细胞的骨髓增生异常综合征相似。
Mod Pathol. 2016 Oct;29(10):1221-31. doi: 10.1038/modpathol.2016.118. Epub 2016 Jul 15.
7
Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.外显子组测序鉴定出急性红细胞白血病中高度复发的体细胞 GATA2 和 CEBPA 突变。
Leukemia. 2017 Jan;31(1):195-202. doi: 10.1038/leu.2016.162. Epub 2016 Jun 15.
8
microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia.miRNA-23a、-27a 和 -24 协同调控 JAK1/Stat3 级联反应，可作为人类急性红细胞白血病的新型治疗靶点。
Oncogene. 2016 Nov 17;35(46):6001-6014. doi: 10.1038/onc.2016.127. Epub 2016 Apr 18.
9
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.比较骨髓中红系细胞比例超过 50%的急性髓系白血病和骨髓增生异常综合征患者的遗传和临床特征。
Haematologica. 2011 Sep;96(9):1284-92. doi: 10.3324/haematol.2011.043687. Epub 2011 May 23.
10
Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.Graffi 鼠逆转录病毒诱导的红系和巨核细胞白血病的基因谱分析。
BMC Med Genomics. 2010 Jan 26;3:2. doi: 10.1186/1755-8794-3-2.
本文引用的文献
1
Improved outcome of acute myeloid leukaemia in Down's syndrome.唐氏综合征患者急性髓系白血病的预后改善。
Arch Dis Child. 1999 Jul;81(1):32-7. doi: 10.1136/adc.81.1.32.
2
Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis.急性红白血病：48例病例的分类、细胞增殖、细胞遗传学及预后评估
Am J Clin Pathol. 1998 Nov;110(5):590-8. doi: 10.1093/ajcp/110.5.590.
3
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.诊断细胞遗传学对急性髓系白血病预后的重要性：对参加医学研究委员会AML 10试验的1612例患者的分析。医学研究委员会成人及儿童白血病工作组。
Blood. 1998 Oct 1;92(7):2322-33.
4
The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy.全口服化疗方案（伊达比星和依托泊苷）用于老年急性髓系白血病治疗：毒性和疗效报告
Leukemia. 1997 Aug;11(8):1193-6. doi: 10.1038/sj.leu.2400726.
6
The PACE (population-adjusted clinical epidemiology) strategy: a new approach to multi-centred clinical research.PACE（人群调整临床流行病学）策略：一种多中心临床研究的新方法。
QJM. 1997 Feb;90(2):147-51. doi: 10.1093/qjmed/90.2.147.
7
Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study.红白血病（急性髓系白血病；FAB-M6）的形态学特征：一项癌症和白血病研究组B（CALGB）的研究
Am J Hematol. 1995 May;49(1):29-38. doi: 10.1002/ajh.2830490106.
8
9
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.急性髓系白血病分类的修订标准建议。法美英协作组报告
Ann Intern Med. 1985 Oct;103(4):620-5. doi: 10.7326/0003-4819-103-4-620.
10
Morphologic, immunologic and cytogenetic studies in erythroleukaemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types.
Br J Haematol. 1990 Jul;75(3):346-54. doi: 10.1111/j.1365-2141.1990.tb04347.x.
Zotero 插件